Deal brings single-cell genomics to China and accelerates Mission Bio’s mission to predict and prevent cancer relapse on a global scale
SOUTH SAN FRANCISCO, Calif. (July 10 2019) Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced that it has launched sales in China through a distribution agreement with Novogene, a leading provider of genomic services and solutions globally. The deal brings the Mission Bio Tapestri™® Platform to the rapidly expanding Chinese market.
China is one of the world’s largest next-generation sequencing (NGS) markets, with enormous opportunities for genomics. Thanks to greater investment into the region’s healthcare infrastructure, the market is poised to explode: recent reports project the country’s DNA sequencing market will reach $2.7 billion by 2022, up from $1.1 billion in 2017. Further, the in vitro diagnostics (IVD) market is expected to double by 2022, growing from $3 billion in 2017.
“The demand for innovative and impactful technologies has required Novogene to bring new products to our customers,” said Ruiqiang Li, Ph.D., founder and CEO of Novogene. “The Mission Bio Tapestri™ Platform has advantages over current offerings, including increased resolution down to 0.1 percent. It is synergistic to the sequencing we offer, and we are excited to be able to offer this unique technology to our customers.”
The Mission Bio Tapestri™ Platform is the only single-cell targeted DNA solution available to more precisely identify cancer cell mutation profiles. Tapestri™’s unique ability to sensitively detect rare cancer subclones and co-occurring cancer mutations offer a precise way to measure therapy response and disease progression.
“We are excited about our partnership with Novogene and increasing our reach into the China market,” said Darrin Crisitello, Chief Commercial Officer of Mission Bio. “Novogene is highly regarded globally across the industry with reach into key accounts that will have significant interest in the Tapestri™ Platform. The adoption of this targeted single-cell DNA analysis has been strong in other parts of the world, and we expect the same uptake in the Chinese market.”
Most recently, researchers at UCSF and Penn leveraged the single-cell technology to track and monitor cancer evolution, revealing the potential for more impactful, dynamic therapies in patients with Acute Myeloid Leukemia (AML). The study, published in Cancer Discovery, is the first-ever study using single-cell DNA analysis to reveal how cancer evolves in response to targeted treatment.
To learn more about Mission Bio and how it’s moving precision medicine forward, visit missionbio.com.
Mission Bio delivers targeted solutions for high impact applications with the Tapestri™ Platform. The Tapestri™ Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows. LabCorp’s Covance Drug Development business will be the first global contract research organization to offer services on the Mission Bio Tapestri™ Platform, supporting biopharmaceutical customers in their need for faster, more precise clinical trials.
The company’s Tapestri™ Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world-leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 32 NGS-related patents, as well as over 580 research papers with total impact factor at more than 4090, including publications in first tiers journals such as Cell, Nature and Science. For more information, visit novogene.com/us-en.
The field is required.